The short version
10 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Dexlansoprazole delayed release
dexlansoprazole · DEXLANSOPRAZOLE 60 mg/1 · Capsule, Delayed Release · Oral · A-S Medication Solutions
NDC 50090-5944-00 · 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE · NDA AUTHORIZED GENERIC · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 49884-0148-11) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$5.08per unit
middle half $3.71–$5.61 · 2,213 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $5.08
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
40%of plans cover it
tier 4 · prior auth 0% · step therapy 3% · qty limit 98%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for dexlansoprazole (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- A-S Medication Solutions LLCUnited Statesrelabel · repack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- NDA022287
- TE code
- AB
- Approval date
- Jan 30, 2009
- Patents / exclusivity
- 24 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 9233103 | Mar 5, 2032 |
| patent | 9233103 | Mar 5, 2032 |
| patent | 8173158*PED | Sep 17, 2030 |
| patent | 8173158*PED | Sep 17, 2030 |
| patent | 8173158 | Mar 17, 2030 |
| patent | 8173158 | Mar 17, 2030 |
| patent | 8871273 | Jan 11, 2028 |
| patent | 8871273 | Jan 11, 2028 |
| patent | 8105626*PED | Mar 27, 2027 |
| patent | 8105626*PED | Mar 27, 2027 |
| patent | 7790755*PED | Feb 2, 2027 |
| patent | 7790755*PED | Feb 2, 2027 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of dexlansoprazole (Capsule, Delayed Release)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | DEXLANSOPRAZOLE 60 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Aphena Pharma Solutions - Tennessee, LLC | DEXLANSOPRAZOLE 30 mg/1 | Aug 27, 2026 | Sep 3, 2026 |
| Alembic Pharmaceuticals Inc. | DEXLANSOPRAZOLE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Inc. | DEXLANSOPRAZOLE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | DEXLANSOPRAZOLE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | DEXLANSOPRAZOLE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | DEXLANSOPRAZOLE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | DEXLANSOPRAZOLE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Par Health USA, LLC | DEXLANSOPRAZOLE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Par Health USA, LLC | DEXLANSOPRAZOLE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Takeda GmbH, Oranienburg | DEXLANSOPRAZOLE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Takeda GmbH, Oranienburg | DEXLANSOPRAZOLE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Takeda Pharmaceuticals America, Inc. | DEXLANSOPRAZOLE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Takeda Pharmaceuticals America, Inc. | DEXLANSOPRAZOLE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Upsher-Smith Laboratories, LLC | DEXLANSOPRAZOLE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Upsher-Smith Laboratories, LLC | DEXLANSOPRAZOLE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | DEXLANSOPRAZOLE 60 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
| Bryant Ranch Prepack | DEXLANSOPRAZOLE 30 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Dexlansoprazole delayed release — NDC 50090-5944-00," retrieved September 3, 2026, https://drugdashboards.com/drug/50090594400.
Free to cite with attribution — see how the data is put together.